Nearly 50 years after the autoimmune nature of type 1 diabetes was discovered, no therapy has been approved to alter the course of the disease at any stage. However, during that same period, technology has been delivering tools to help patients achieve better glycemic control and reduce the burden of the disease. With the imminent arrival of fully automated artificial pancreas systems that will continue to improve control and quality of life, it appears that we are on the verge of a major technological breakthrough that will significantly impact diabetes care. These devices have such a high degree of potential that they are, at times, mentioned as a virtual cure for the disease—a first for technology in this space. As such, these devices will undoubtedly alter the research landscape in a field that has predominantly been occupied by immunotherapies. This article reviews the history of type 1 diabetes and compares and contrasts the advancements that have come from the world of technology and immunology alike at this important crossroads in care that we are currently in.
Type 1 diabetes Artificial pancreas Immunotherapies
This is a preview of subscription content, log in to check access.
Compliance with ethical standards
Conflict of interest
J Pettus was a consultant for Novo Nordisk, Sanofi, Mannkind, Insulet. He received research support from JDRF, Viacyte. M. Von Herrath was an employee for Novo Nordisk.
Human and animal rights statement
This article does not contain any studies with human or animal subjects performed by the any of the authors.
Bottazzo GF, Florin-Christensen A, Doniach D (1974) Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 2(7892):1279–1283CrossRefPubMedGoogle Scholar
Stiller CR et al (1984) Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223(4643):1362–1367CrossRefPubMedGoogle Scholar
Sherry N et al (2011) Teplizumab for treatment of type 1 diabetes (protege study): 1-year results from a randomised, placebo-controlled trial. Lancet 378(9790):487–497CrossRefPubMedPubMedCentralGoogle Scholar